Syncom Formul.

Which are the latest news on Syncom Formul.?

Why is Syncom Formulations (India) Ltd falling/rising?

As of 05-Sep, Syncom Formulations (India) Ltd's stock price is declining at 20.56, down 3.47% recently, but it has shown strong long-term gains with a year-to-date increase of 44.08%. Despite the current downturn, the stock remains above its moving averages and has seen increased investor participation.

As of 05-Sep, Syncom Formulations (India) Ltd is experiencing a decline in its stock price, currently at 20.56, which reflects a change of -0.74 or -3.47%. This decrease is part of a broader trend, as the stock has been losing value for the last two days, resulting in a total decline of -3.88% during this period. <BR><BR>Despite this recent downturn, the stock has shown strong performance over longer time frames, with a 1-week increase of +5.65%, a 1-month rise of +54.82%, and a year-to-date gain of +44.08%. However, today's performance indicates that it has underperformed its sector by -3.02%. <BR><BR>On a positive note, Syncom Formulations is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a generally upward trend in the stock's performance prior to this recent decline. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 32.58% against the 5-day average. <BR><BR>Overall, while the stock is currently falling, it has demonstrated significant gains over the longer term, and the increase in trading volume indicates ongoing interest from investors.

Who are in the management team of Syncom Formul.?

The management team of Syncom Formul includes Kedarmal Bankda (Chairman & Wholetime Director), Vijay Shankarlal Bankda (Managing Director), Rinki Bankda (Whole-time Director), and several independent directors, along with Vaishali Agrawal as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Syncom Formul includes the following members:<BR><BR>1. **Kedarmal Bankda** - Chairman & Wholetime Director<BR>2. **Vijay Shankarlal Bankda** - Managing Director<BR>3. **Rinki Bankda** - Whole-time Director<BR>4. **Vinod Kumar Kabra** - Independent Director<BR>5. **Krishna Das Neema** - Independent Director<BR>6. **Praveen Jindal** - Independent Director<BR>7. **Ruchi Jindal** - Independent Director<BR>8. **Vaishali Agrawal** - Company Secretary & Compliance Officer<BR>9. **Ritesh Kumar Lunkad** - Independent Director<BR>10. **Ankit Jain** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Syncom Formul. do?

Syncom Formulations (India) Ltd is a micro-cap pharmaceutical company established in 1988, with recent quarterly net sales of ₹126 Cr and net profit of ₹25 Cr. It has a market cap of ₹1,828 Cr and key metrics include a P/E ratio of 21.00 and a return on equity of 18.41%.

Overview: <BR>Syncom Formulations (India) Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1988 as a private limited company, Syncom Formulations (India) Ltd was converted into a public limited company in June 1992. The latest reported quarterly results indicate net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 126 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 25 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,828 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.27 <BR>Return on Equity: 18.41% <BR>Price to Book: 4.41<BR><BR>Contact Details: <BR>Address: 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd Mumbai Maharashtra : 400093 <BR>Tel: 91-22-30887744 <BR>Email: info@sfil.in / finance@sfil.in <BR>Website: http://www.sfil.in

Who are the peers of the Syncom Formul.?

Syncom Formul.'s peers include Windlas Biotech, Shukra Pharma, Hester Bios, NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, Fermenta Biotec, Sigachi Indust, and Sakar Healthcare. Shukra Pharma shows the highest 1-year return at 69.45%, while Syncom Formul. has a 1-year return of 16.09%.

Peers: The peers of Syncom Formul. are Windlas Biotech, Shukra Pharma., Hester Bios, NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, Fermenta Biotec., Sigachi Indust., and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shukra Pharma., Amrutanjan Healt, NGL Fine Chem, Jagsonpal Pharma, and Sigachi Indust., while Average management risk is found at Windlas Biotech, Hester Bios, Syncom Formul., Fermenta Biotec., and Sakar Healthcare. Growth is Excellent at Shukra Pharma. and Good at Amrutanjan Healt, while Below Average growth is seen at Windlas Biotech, Hester Bios, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, Fermenta Biotec., Sigachi Indust., and Sakar Healthcare. Capital Structure is Excellent at Windlas Biotech, Shukra Pharma., Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, and Sigachi Indust., while Below Average is noted at Hester Bios and Fermenta Biotec., and Average at Sakar Healthcare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shukra Pharma. at 69.45%, while the lowest is Amrutanjan Healt at -26.26%. Syncom Formul.'s own 1-year return is 16.09%, which is higher than Amrutanjan Healt but lower than Shukra Pharma. Additionally, Amrutanjan Healt is the only peer with a negative six-month return.

How big is Syncom Formul.?

As of 31st August, Syncom Formulations (India) Ltd has a market capitalization of 1,828.00 Cr, with recent Net Sales of 497.80 Cr and a Net Profit of 85.53 Cr.

As of 31st August, Syncom Formulations (India) Ltd has a market capitalization of 1,828.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 497.80 Cr and a Net Profit of 85.53 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 342.16 Cr and Total Assets of 413.28 Cr.

Should I buy, sell or hold Syncom Formulations (India) Ltd?

Has Syncom Formulations (India) Ltd declared dividend?

Yes, Syncom Formulations (India) Ltd has declared a 10% dividend, with an ex-date of September 23, 2026. While recent performance shows a decline over the past year, total returns have been positive over longer periods.

Syncom Formulations (India) Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Ex-date: 23 Sep 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 10.76%, the dividend return was 0.73%, resulting in a total return of 11.49%.<BR><BR>Over the past 6 months, the price return was 8.63%, the dividend return was 0.74%, leading to a total return of 9.37%.<BR><BR>In the 1-year period, the price return was -13.81%, with a dividend return of 0.58%, resulting in a total return of -13.23%.<BR><BR>For the 2-year period, the price return was -3.42%, the dividend return was 0.53%, culminating in a total return of -2.89%.<BR><BR>In the last 3 years, the price return was 66.63%, with a dividend return of 1.15%, leading to a total return of 67.78%.<BR><BR>Over the past 4 years, the price return was 65.9%, the dividend return was 1.50%, resulting in a total return of 67.4%.<BR><BR>In the 5-year period, the price return was 108.92%, with a dividend return of 2.18%, culminating in a total return of 111.1%.<BR><BR>Overall, Syncom Formulations (India) Ltd has declared a dividend, which reflects positively in their returns, particularly over longer periods, where total returns have been significantly higher. However, the recent 1-year performance shows a decline, indicating some volatility in the company's stock performance.

When is the next results date for Syncom Formulations (India) Ltd?

The next results date for Syncom Formulations (India) Ltd is 11 August 2026.

The next results date for Syncom Formulations (India) Ltd is scheduled for 11 August 2026.

Are Syncom Formulations (India) Ltd latest results good or bad?

Syncom Formulations (India) Ltd's latest results show strong profitability growth with a 42.28% increase in net profit, but revenue declined 9.05% year-on-year, raising concerns about sustainability. The company's reliance on non-operating income for a significant portion of profits suggests a cautious outlook despite improvements in margins.

Syncom Formulations (India) Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹25.17 crore, which is a significant increase of 42.28% year-on-year and a 33.10% rise from the previous quarter. This indicates strong profitability growth, which is a positive sign.<BR><BR>However, the revenue for the same quarter was ₹135.41 crore, reflecting a decline of 9.05% year-on-year, although it showed a recovery with a 17.60% increase compared to the previous quarter. This revenue volatility raises concerns about the sustainability of the company's core operations.<BR><BR>The operating margin improved to 16.25%, up 433 basis points from the previous year, showcasing better cost management. Additionally, the profit after tax (PAT) margin also saw a notable increase to 18.59%, up 671 basis points year-on-year.<BR><BR>Despite these positive indicators, there are significant concerns regarding the company's reliance on non-operating income, which constituted 43.18% of profit before tax in Q4 FY26. This raises questions about the quality of earnings and the sustainability of profit growth.<BR><BR>Overall, while the recent quarterly results show improvements in profitability and margins, the underlying challenges related to revenue contraction and dependence on non-operating income suggest a cautious outlook for the company. Investors should monitor future performance closely to assess whether these gains can be sustained.

Is Syncom Formul. overvalued or undervalued?

As of November 18, 2025, Syncom Formul. is fairly valued with a PE ratio of 24.53, compared to its peers like Sun Pharma at 36.56 and Cipla at 22.49, indicating reasonable pricing relative to its earnings growth potential despite underperforming the Sensex year-to-date.

As of 18 November 2025, the valuation grade for Syncom Formul. has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 24.53, an EV to EBITDA ratio of 21.00, and a PEG ratio of 0.27. These ratios suggest that while the company is priced reasonably compared to its earnings growth potential, it is not undervalued.<BR><BR>In comparison to its peers, Syncom Formul. stands out against Sun Pharma, which is considered expensive with a PE ratio of 36.56, and Cipla, which is attractive with a PE ratio of 22.49. The fair valuation of Syncom Formul. indicates that it is positioned well within the industry, especially when compared to the higher valuations of some competitors. Notably, while the stock has underperformed the Sensex year-to-date, it has shown significant returns over longer periods, reflecting its potential for growth.

How has been the historical performance of Syncom Formul.?

Syncom Formul. has experienced significant fluctuations in financial performance, with net sales increasing to 465.01 Cr in March 2025 from 263.39 Cr in March 2024, but down from a peak of 21,966.32 Cr in March 2022. Despite recent improvements in key metrics, the company's historical data reflects volatility.

Answer:<BR>The historical performance of Syncom Formul. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Syncom Formul. reported net sales of 465.01 Cr for the year ending March 2025, a substantial increase from 263.39 Cr in March 2024 and 224.25 Cr in March 2023. However, this is a stark contrast to the exceptionally high net sales of 21,966.32 Cr recorded in March 2022. The company's total operating income mirrored this trend, reaching 465.01 Cr in March 2025, up from 263.39 Cr in the previous year. The total expenditure, excluding depreciation, was 410.88 Cr in March 2025, which also increased from 233.74 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 71.56 Cr, showing a rise from 43.18 Cr in March 2024, while profit before tax was reported at 65.51 Cr, up from 33.95 Cr. The profit after tax for March 2025 was 49.43 Cr, compared to 25.31 Cr in March 2024. The earnings per share (EPS) improved to 0.53 in March 2025 from 0.27 in March 2024. On the balance sheet, total assets increased to 413.28 Cr in March 2025 from 404.66 Cr in March 2024, while total liabilities also rose to 413.28 Cr from 404.66 Cr. The cash flow from operating activities was positive at 23.00 Cr in March 2025, a recovery from a negative cash flow of -5.00 Cr in March 2024. Overall, while Syncom Formul. has shown improvement in several financial metrics in the latest fiscal year, the historical data reflects a volatile performance with significant peaks and troughs.

Is Syncom Formul. technically bullish or bearish?

As of November 4, 2025, the market trend has shifted to a moderate bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bullish signal from Dow Theory.

As of 4 November 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. The KST is also bearish on the weekly chart, contributing to the overall bearish sentiment. The Dow Theory shows a mildly bullish signal on the weekly, but this is overshadowed by the predominant bearish indicators.

Who are the top shareholders of the Syncom Formul.?

The top shareholders of Syncom Formul include promoters led by Kedarmal Shankarlal Bankda, who holds 12.44%, and individual investors with a collective stake of 45.2%. Foreign institutional investors hold 0.11%, while mutual funds have a negligible presence, and there are no pledged promoter holdings.

The top shareholders of Syncom Formul include the promoters, who hold the majority of the shares. The promoter with the highest holding is Kedarmal Shankarlal Bankda, with a stake of 12.44%. Additionally, individual investors collectively hold 45.2% of the shares. There are also 12 foreign institutional investors (FIIs) that hold a small portion, totaling 0.11%, while mutual funds have a negligible presence with 2 schemes holding 0.0%. There are no pledged promoter holdings reported.

What is the bonus history of the Syncom Formul.?

Syncom Formulations (India) Ltd announced a bonus issue on August 19, 2013, in the ratio of 5:2, meaning shareholders received five additional shares for every two shares held, with a record date of August 20, 2013.

Syncom Formulations (India) Ltd has a bonus history that includes a significant bonus issue announced on August 19, 2013. The company issued a bonus in the ratio of 5:2, with the record date for this bonus being August 20, 2013. This means that for every two shares held, shareholders received five additional shares. If you have any more questions about the company or its financial activities, feel free to ask!